Skinny, Inc. Part 1: The Canadian connection to Ozempic
Dr. Daniel Drucker’s research helped pave the way for Ozempic, the blockbuster GLP-1 class drug. The endocrinologist has been researching the effects on Ozempic’s active ingredient semaglutide in the body for decades. Today, he’ll show us around his lab and explain how a stout lizard kept in a freezer helped unlock the science behind a drug taken by more than a million Canadians. Then, health reporter Kelly Grant tells us about rising obesity rates in Canada, and we’ll hear from a doctor who prescribes GLP-1s – and a patient who takes them.
You May Also Like

700 WLW On-Demand
WLW-AM (WLWAM)

Tech News Daily
brief.news

Israel Today: Ongoing War Report
Israel Today: Ongoing War Report

The Epstein Chronicles
Bobby Capucci

Durham News Today | 2 Min News | The Daily News Now!
The Daily News Now!

Plus
Český rozhlas

Good Morning Liberty
Good Morning Liberty

The Jacksonville Jaguars Official Podcast Network
Jacksonville Jaguars

The John Batchelor Show
The John Batchelor Show

1A
NPR
Community discussion